Verified Clinical Trials Pipeline
Live tracking of all trials addressing Duffy antigen variation, oncology dose modifications, and malaria invasion.
Recent Peer-Reviewed Publications
Foundational and latest 2026 hematology research papers indexed on NCBI/PubMed.
ACKR1 / DARC Erythrocyte Sink Biology
Understanding atypical chemokine receptor 1 dynamics in health and systemic disease.
In Duffy-positive individuals, red cell ACKR1 binds inflammatory chemokines (CXCL1, CXCL8, CCL2) with nanomolar affinity without initiating G-protein signaling. Erythrocytes thus act as a "circulatory sink," buffering free plasma chemokine spikes.
In Duffy-null individuals (lacking erythroid ACKR1 expression via the -46T>C GATA-1 mutation), baseline circulating chemokine profiles are altered. Endothelial ACKR1 expression remains intact, facilitating targeted post-capillary venule leukocyte transcytosis.
Chronically transfused hemoglobinopathy patients with Duffy-null phenotype are at significant risk of developing high-titer anti-Fyª alloantibodies upon exposure to standard donor units. Extended donor matching is clinically essential.
Protocol Recommendations for Clinical Trial Sponsors
Eliminating structural trial exclusion of diverse ancestral cohorts.
Most oncology and immunotherapy clinical trial protocols mandate an Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L as an inclusion criterion. This single entry requirement automatically disqualifies 15% to 20% of eligible Black oncology patients despite completely normal bone marrow reserves and zero increased infection risk.
"Inclusion Criteria: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10^9/L, OR ANC ≥ 1.0 × 10^9/L in patients with confirmed or suspected Duffy-Null Associated Neutrophil Count (DANC / ACKR1 rs2814778 mutation), provided other baseline laboratory parameters are clinically acceptable."
Collaborative Academic Research & Clinical Study Partnerships
Connect with our research desk regarding observational studies, clinical protocol diversity amendments, or de-identified epidemiological research.
Frequently Asked Research & Biopharma Questions
Authoritative analysis on trial inclusivity, FDA Diversity Action Plans, chemokine kinetics, and vaccine development.
How does the conventional ANC ≥ 1.5 × 10⁹/L eligibility cutoff undermine clinical trial diversity?
Historically, clinical trial protocols routinely adopt an empirical eligibility floor of ANC ≥ 1.5 × 10⁹/L (1,500 /µL) to guard against drug-induced myelosuppression. However, published oncology evaluations show that 76.5% of Phase 3 cancer trials enforce eligibility criteria that inherently exclude individuals within the healthy Duffy-null reference range (Hibbs et al., JAMA Network Open 2024).
Because 67% to 73% of Black individuals and significant proportions of Middle Eastern populations exhibit the Duffy-null phenotype, this uniform criterion creates an artificial barrier to participation, compromising trial accrual and conflicting with FDA Diversity Action Plan mandates enacted under FDORA.
What regulatory language can sponsors insert into IND/NDA protocols to safely accommodate DANC?
Sponsors can modernize Section 4 (Eligibility Criteria) with tiered hematologic inclusion thresholds:
"Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L, OR ANC ≥ 1.0 × 10⁹/L for participants with documented Duffy-null phenotype [Fy(a-b-) serology or ACKR1 rs2814778 c.-67T>C homozygosity] and no clinical history of recurrent or severe bacterial infections."
This formulation has been frequently accepted in FDA-regulated clinical investigations without clinical holds. However, final acceptability remains subject to FDA and Institutional Review Board (IRB) approval on a protocol-by-protocol basis based on investigational drug toxicity profiles.
Operational Note for Clinical Ops: Screening for the Duffy phenotype involves minimal logistical friction. Red blood cell serotyping [Fy(a-b-)] can be completed by any local hospital blood bank via standard hemagglutination within hours, or targeted ACKR1 PCR can be added to central laboratory screening panels with routine 48-hour turnaround.
Does erythrocyte ACKR1 absence alter pharmacokinetics or pharmacodynamics of chemokine-targeted therapies?
Yes. Red blood cell ACKR1 acts as a physiological sink and buffering reservoir for pro-inflammatory CXC and CC chemokines (such as CXCL1, CXCL7, CXCL8/IL-8, CCL2, and CCL5). In Duffy-null cohorts devoid of erythrocyte ACKR1, free circulating chemokine kinetics and reservoir clearance dynamics differ significantly.
Compounds designed to inhibit chemokine receptors (e.g., CXCR1/2 or CCR2 antagonists) or biologics binding circulating cytokines may show divergent exposure-response profiles. Clinical protocol NCT02249117 formally demonstrated measurable pharmacokinetic divergence, underscoring the necessity of stratifying by Duffy genotype in early Phase I/II PK/PD modeling.
Is there evidence of increased treatment-emergent adverse events (TEAEs) or febrile neutropenia in Duffy-null patients receiving cytotoxic agents?
Evidence from oncology cohorts indicates that constitutional Duffy-null status does not impair bone marrow reserve mobilization or recovery kinetics. While studies show no inherent baseline infection risk, optimal genotype-adjusted ANC thresholds for cytotoxic chemotherapy dosing are not yet codified in ASCO or NCCN guidelines and remain an active area of ongoing research.
What are the implications of Plasmodium vivax alternative invasion mechanisms for vaccine research?
Erythrocyte Duffy-null status was long considered an absolute barrier against Plasmodium vivax infection. However, genomic surveillance has confirmed clinical P. vivax parasitemia in Duffy-negative individuals across multiple endemic regions.
Parasite invasion in Duffy-negative hosts involves alternative pathways, including PvRBP2b interaction with the transferrin receptor 1 (TfR1/CD71) on reticulocytes. Recent ex vivo data indicate that invasion mechanisms involve redundant, multi-ligand interactions, informing ongoing multi-target malaria vaccine research.